

CURRICULUM VITAE Eduardo Lasalvia-Prisco, MD

EDUCATION

- Doctor in Medicine 1968. Residency 1968-1970: Medical School, University of Uruguay (1961-1968)
- Degree in Biological Sciences, 1969: School of Sciences, University of Uruguay

SPECIALTIES AND POST-GRADUATE STUDIES 1975- 1985

- Internist, Internal Medicine Degree, Post-Graduate School of the School of Medicine, University of Uruguay
- Oncologist, Clinical Oncology Degree, Post-Graduate School of the School of Medicine, University of Uruguay
- Specialist in Clinical Laboratory, Biochemistry
- Cancerologie, University of Paris, Institute of Cancerologie et d'Immunogenetique. Villejuif: Certificate of Improvement in Cancerologie, 1970
- Hematology, University of Paris, Paul Brousse Hospital, Group Hopitalier Gustave Roussy. Certificate of Improvement in Hematology, 1976

AWARDS, SCHOLARSHIPS, DISTINCTIONS, TECHNICAL AND SCIENTIFIC MISSIONS

In Uruguay, the School of Medicine has two annual Awards, the Annual Scholarships that are granted to the 2 graduates with the most outstanding academic merits according to a special tribunal. The University of the Uruguay also grants every year among the graduates of all the University Schools that have obtained the Annual Scholarships, two awards denominated Artigas Scholarships, to those who gather the highest academic merits according to a special tribunal. Independently, several types of Scholarships for studies of Improvement are offered by different Governments to the university graduates who are selected by their educational and academic records.

- Annual Scholarship, School of Medicine, University of Uruguay, 1968
- Artigas Scholarship, University of Uruguay, 1968
- Scholarship of Improvement of the Government of France
- Scholarship as Invited Investigator of the Government of France
- Mission of Oncological Research Coordination. Birbeck College London
- Mission of Multicentric Coordination in the Oncological Research Program, Department of Tumoral Biology. Institute Karolinska. Stockholm. Sweden
- Scholarship of Improvement of the Government of Spain. Hematology Program. Farreras Valenti-Ciril Rozman Clinic, Clinical Hospital, Barcelona, Spain
- Title of Master of the Latin American Medicine. Argentina Medical Association, Argentina
- Mission of the Ministry of Health of Uruguay to the National Cancer Institute, USA
- Uruguayan delegate to the Pan-American Health Organization Meeting
- Special guest to the Annual Meeting of the Executive Committee of the Pan-American Health Organization
- Special guest to the First International Congress of Italian Scientists in the World (Primo Convegno internazionale degli Scienziati italiani nel mondo (Roma, 10-12 marzo 2003), Government of Italy.
- Member of the Scientific Board of Journal of Clinical and Biological Research

- Member of the Scientific Board of Immunology and Immunotherapy
- Member of the Scientific Board of Cancer Chemotherapy and Pharmacology

FACULTY POSITIONS, SCHOOL OF MEDICINE (1963-1993)

The academic career in the School of Medicine of Uruguay, as well as in all the other Schools of the University of Uruguay, consists of 5 successive hierarchical levels (Grade 1 to 5). All the permanent positions are accessed by an open contest exam. Grade 5, Professor, is the highest position. The academic positions duties are: education of pre-degree and post-degree students, scientific research and, when appropriate, direct clinical practice in Public Hospitals. In Uruguay, there is only one School of Medicine, part of the University of Uruguay, which is a State University.

- Department Assistant 1 (Grade 1). Department of Biochemistry. School of Medicine, University of Uruguay
- Department Assistant 2 (Grade 2). Department of Biochemistry. School of Medicine, University of Uruguay
- Assistant Professor (Degree 3). Department of Biochemistry. School of Medicine, University of Uruguay
- Associate Professor (Degree 4). Department of Biochemistry. School of Medicine, University of Uruguay
- Professor and Chairman (Grade 5): 1977-1984 Department of Biochemistry. School of Medicine, University of Uruguay
- Resident, Department of Medicine (Grade 1)
- Department Assistant 2 (Grade 2). Department of Medicine. School of Medicine, University of the Uruguay
- Assistant Professor (Grade 3). Department of Medicine. School of Medicine, University of the Uruguay
- Associate Professor (Grade 4) Department of Medicine. School of Medicine, University of the Uruguay
- Professor and Chairman (Grade 5): 1984-1994 Department of Medicine. School of Medicine, University of the Uruguay

PROFESSIONAL ACTIVITY - CLINICAL PRACTICE (1963-2004)

The Health System in Uruguay has 2 sub-systems, one public and one private. The public health Subsystem offers coverage 50% of the population through a net of General Hospitals and Specialized Institutes. The private health Subsystem covers the rest of the population through pre-payment managed care organizations (equivalent to the Health Maintenance Organizations or HMOs).

- Director of the National Cancer Institute of Uruguay: 1977-2002 (Public Health System)
- Chairman of the Department of Medicine of the Uruguayan Medical Corporation, MUCAM (Private Health System).
- Chairman of the Oncology Department of the Uruguayan Medical Corporation, MUCAM (Private Health System).
- Chief of Staff, Clinical Oncology, of the Medical Center of the Medical Union of Uruguay, CASMU (Private Health System).
- Medical Director of Interdoctors, Medical Center (Private Health System).

- ❑ Chief of the Applied Biomedical Investigations Service. Ministry of Public Health of Uruguay (Public Health System)
- ❑ Laboratory Assistant, Ministry of Public Health of Uruguay (Public Health System)

PROFESSIONAL ACTIVITY – PHARMACEUTICAL INDUSTRY (1963-2004)

- ❑ Medical Director, in pharmaceutical/biotech companies. He has directed and executed clinical development programs (phase II, III) in Oncology. Expertise in providing scientific support and input to the evaluation of in-licensing opportunities, early development projects and phase IIIb/IV Clinical Development plans; develop Principal Opinion Makers and or Panel Discussants, within the scope of the Clinical Development Unit; support business development by identifying and evaluating business opportunities and by identifying and anticipating all industry market trends related to Oncology therapeutics.
- ❑ Design of new pharmaceutical products.
- ❑ All steps of product design, manufacturing, approval and marketing.

ACTIVITIES IN MEDICAL EDUCATION AND HEALTH POLICY PLANNING

- ❑ Organization and Implementation of the First Course of Pre-Medical Education of Uruguay. School of Medicine. University of Uruguay
- ❑ Member of the Commission for Reformulation of the Plan of Studies. School of Medicine. University of Uruguay
- ❑ Member of the University Cloister on behalf of the Faculty
- ❑ Member of the University Cloister on behalf of the Graduates
- ❑ Member of the Directive Commission of the Medical Residences Program (Coordination School of Medicine-Ministry of Public Health).
- ❑ President of the Directive Council of the Uruguayan Medical Corporation, MUCAM (Private Health System).
- ❑ Founder and Member of the Honorary Commission Against Cancer of Uruguay
- ❑ Founder and Member of the First National Bank of Antitumoral Drugs of Uruguay
- ❑ Founder of the National Breast Cancer Program of the Ministry of Public Health of Uruguay
- ❑ National Director of Health of the Ministry of Public Health of Uruguay
- ❑ Technical Director of the National Fund of Resources of Uruguay (National System of Financing Highly Specialized Medicine)

SCIENTIFIC SOCIETIES

- ❑ American Society of Clinical Oncology- ASCO – Active Member
- ❑ Society of Internal Medicine of Uruguay. Permanent member
- ❑ Society of Medical and Pediatric Oncology of Uruguay. Founder Member and First President
- ❑ Society of Hematology of Uruguay. Founder Member
- ❑ Society of Clinical Pathology of Uruguay. Permanent Member
- ❑ Argentina Medical Association. Founder Member (1982). Honorary Foreign Member (1982). Advisory Member (1987). Consultant Member (1987).
- ❑ European Organization for the Research of Cancer. Correspondent Member
- ❑ South American School of Oncology. Directive Member

SCIENTIFIC PUBLICATIONS-BOARD MEMBER

- ❑ Cancer. Spain
- ❑ Clinical Oncology. Association of Clinical Oncology, Argentina

SCIENTIFIC PUBLICATIONS-INVITATION AS REVIEWER FOR:

- ❑ AJCO. American Journal of Clinical Oncology, US
- ❑ APS. Acta Pharmacologica Sinica, China
- ❑ MRR. Medicinal Research Reviews

THE MOST RELEVANT SCIENTIFIC PUBLICATIONS

Author or Co-author of 155 papers published in scientific journals and Medical Congresses Acts. Among those, 58 are publications in international forums, peer review journals. The following is a selection of the 10 most relevant publications related to the main field of research, maintained for more than 30 years.

- ❑ Extraction of an Inhibitor of DNA synthesis from human peripheral blood lymphocytes and bovine spleen. E. Lasalvia, E. García-Giralt and A. Macieira-Coelho. Rev. Europ. Etudes Clin. et Biol. 1970, XV: 789-792
- ❑ Evidence for to lymphocytic chalone. E. García-Giralt, E. Lasalvia, I. Florentin and G. Mathe. Rev. Europ. Etudes Clin. et Biol. 1970, XV: 1012-1015
- ❑ Suppression of Graft-vs. -Host Reaction by to Spleen Extract. E. García - Giralt, VH Morales, E. Lasalvia and G. Mathe. The Journal of Immunology, 1972,109,4:878-880
- ❑ Prevention of Graft versus Host Reaction by incubation of lymphoid cells with to splenic extract (Not Affecting the Repopulation of the Hemopoietic tissue). E. García-Giralt, VH Morales, B. Bizzini and E. Lasalvia. Cell Tissue Kinet, 1973,6:567-571
- ❑ Decreased lymphoid chalone rate in the spleens of lymphoma patients. E. Lasalvia, A. Luquetti, C. Oehninger, and E. García-Giralt. Proc. XV Congress of the International Society of Hematology, 1974
- ❑ Autologous Induction of tumor fibrogenesis (Inducción autóloga de fibrogenesis tumoral) (Autologous Induction of tumor fibrogenesis). Lasalvia E, Cucchi S, DeStefani E, Deneo H, Fierro L, Mechoso B, Larrañaga J, Vázquez J. Neoplasia (Spain), 1995(1): 5-10
- ❑ Anti-metastatic effect of a blood fraction from cancer patients. Lasalvia E, Cucchi S, Carlevaro T, Vázquez J, Riotorto R, Fierro L. Proc 31st Annual Meeting of ASCO, May 1995: Abs. 730
- ❑ Serum Markers Variation Consistent with Autoschizis Induced by Ascorbic Acid–Menadione in Patients with Prostate Cancer. Eduardo Lasalvia-Prisco, Silvia Cucchi, Jesús Vázquez, Eduardo Lasalvia-Galante, Wilson Golomar and William Gordon. Medical Oncology; 2003; 20 (1): 45-52
- ❑ Antitumoral Effect of a Vaccination Procedure with an Autologous Hemoderivative. Eduardo Lasalvia-Prisco, Silvia Cucchi, Jesús Vázquez, Eduardo Lasalvia-Galante, Wilson Golomar and William Gordon; Cancer Biology & Therapy; 2003, 2 (2):155-160.
- ❑ Breast Cancer: Autologous Immunogenicity Elicited by Chemotherapy. Eduardo M Lasalvia, Silvia Cucchi, Jesus Vázquez, Eduardo Lasalvia-Galante, Wilson Golomar, William Gordon; Proc. 39th Annual Meeting of ASCO, May 2003: Abs. 746
- ❑ Insulin-induced Enhancement of Antitumoral Response to Methotrexate in Breast Cancer Patients. Eduardo M Lasalvia-Prisco, Silvia Cucchi, Jesús Vázquez, Eduardo Lasalvia-Galante, Wilson Golomar, William Gordon. Cancer Chemother and Pharmacol (2004) 53: 220-224.

- ❑ Colorectal Cancer: Autologous Immunogenicity in Chemotherapy (5FU) Pre-Treated Patients. E. Lasalvia-Prisco, S. Cucchi, J. Vazquez, E. Lasalvia-Galante, W. Golomar, F. Cotto, R. Otero; Proc 40th Annual Meeting of ASCO, May 2004, Abs. 2593
- ❑ Breast Cancer: Updated Vaccination With An Autologous Hemoderivative in Changing Tumor Antigen Library. E. Garcia-Giralt, E. Lasalvia-Prisco, S. Cucchi, J. Vazquez; Proc 40th Annual Meeting of ASCO, May 2004, Abs 2594
- ❑ Breast Cancer: Role of Tumor Associated Antigens and Regulatory Cells [CD4+CD25+] as Targets of the Immune Response elicited by an Anti-progressive Autologous Hemoderivative Vaccine. E. Garcia-Giralt, E. Lasalvia-Prisco, S. Cucchi, J. Vazquez, E. Lasalvia-Galante, W. Golomar. Proc 41st Annual Meeting of ASCO, May 2005, Abs. 2589
- ❑ Colorectal Cancer: Comparative effects of an Autologous Hemoderivative Vaccine with a CEA vaccine and/or an autologous [CD4+CD25+] vaccine. E. Lasalvia-Prisco, E. Garcia-Giralt, S. Cucchi, J. Vazquez, E. Lasalvia-Galante, W. Golomar. Proc 41st Annual Meeting of ASCO, May 2005, Abs. 2596
- ❑ Advanced Colon Cancer: Antiprogressive Immunotherapy Using an Autologous Hemoderivative. E. Lasalvia-Prisco, E. Garcia-Giralt, S. Cucchi, J. Vázquez, E. Lasalvia-Galante, W. Golomar. Medical Oncology, 2006, (23) 1: 91-104.
- ❑ Advanced Breast Cancer: Antiprogressive Immunotherapy Using a Thermostable Autologous Hemoderivative. Eduardo Lasalvia-Prisco, Emilio Garcia-Giralt, Silvia Cucchi, Jesús Vázquez, Eduardo Lasalvia-Galante, Wilson Golomar. Breast Cancer Res Treat (2006) 100: 149-160.
- ❑ Prostate cancer: autologous immunotherapy optimized by indoleamine- 2,3-dioxygenase (IDO)-inhibitor as immune-tolerance breaker. E. Lasalvia-Prisco, E. Garcia-Giralt, S. Cucchi, J. Larrañaga. Proc. Am Soc Clin Oncol (ASCO), 42nd Annual Meeting 2006: Abs. 12509
- ❑ Ovarian cancer: autologous immunotherapy optimized by remote adjuvancy of a silicate-induced granuloma. E. Garcia-Giralt, E. Lasalvia- Prisco, S. Cucchi, E. Lasalvia-Galante, J. Vazquez, W. Golomar, J. P. Vincent. Proc. Am Soc Clin Oncol (ASCO), 42nd Annual Meeting 2006: Abs. 12515
- ❑ Prostate cancer: vaccine Sentinel Immunized Node (SIN) target for adjuvant locoregional chemotherapy in autologous vaccine. E. Lasalvia-Prisco, E. Garcia-Giralt, S. Cucchi et al. Am Soc Clin Oncol (ASCO), 43rd Annual Meeting, June 1-5, 2007: Abs. 13500
- ❑ Breast cancer: draining lymph node of vaccination site targeted by adjuvant GM-CSF in an autologous vaccine. E. Garcia-Giralt, E. Lasalvia-Prisco, S. Cucchi et al. Am Soc Clin Oncol (ASCO), 43rd Annual Meeting, June 1-5, 2007: Abs. 13506
- ❑ Immunotherapeutic Site in Breast Cancer: a new methodology for the Autologous Thermostable Hemoderivative Cancer Vaccine (ATH-CV). E. Garcia-Giralt, E. Lasalvia-Prisco, S. Cucchi et al. European Institute of Oncology, 9th Milan Breast Cancer Conference, June 20-22, 2007, Innovation in Cancer Research, Chair U. Veronesi- A. Goldhrish. Coord: S. Cinieri, M. Colleoni, S. Zurrida. Section I, I-1

- ❑ Conditioning of vaccine sentinel lymph node as adjuvant of Autologous Hemoderivative Breast Cancer Vaccine. Lasalvia-Prisco E, Garcia-Giralt E, Cucchi S, et al. 14th European Cancer Conference. Barcelona, Spain, September 2007: Poster 804
- ❑ Advanced Ovarian Cancer: Vaccination Site Draining Lymph Node as Target of Immunomodulative Adjuvant in Autologous Cancer Vaccine. E. Lasalvia-Prisco, E. Garcia-Giralt, S. Cucchi et al. *Biologics: Targets & Therapy*, October 2007, 1 (2):173-181
- ❑ Erythrocytes as autologous-vaccine carriers targeted in breast cancer sentinel lymph node. E. García-Giralt, E. Lasalvia- Prisco, S. Cucchi et al. ASCO 2008. *J Clin Oncol* 26: 2008 (May 20 suppl; Abs 14018)
- ❑ Erythrocytes as Autologous-Vaccine Carriers in Advanced Prostate Cancer. E. Lasalvia-Prisco, E. Garcia-Giralt, E. Lasalvia-Galante et al. ASCO 2008 *J Clin Oncol* 26: 2008 (May 20 suppl; Abs 14017)
- ❑ Randomized phase II clinical trial of Chemo-immunotherapy in Advanced Non-Small Cell Lung Cancer. E. Lasalvia-Prisco, E. Garcia-Giralt, J. Vázquez et al. *Biologics: Targets & Therapy* 2008;2(3) 555–561 Online Early: www.dovepress.com
- ❑ From Classic Autohemotherapy to Autologous Hemoderivative Cancer Vaccine through a drug and drug-carrier Immunomodulatory Adjuvant System. Lasalvia-Prisco E, Garcia-Giralt E, Vázquez J, Cucchi S, Lasalvia- Galante E, Larrañaga J. Presented at ERLICH II, 2nd World Conference, Oct 3-5, 2008 Nurnberg, Germany

COMMENTS ABOUT OUR WORK

- ❑ Commentary: A New Twist on Autologous Cancer Vaccines. Leisha A. Emens MD. PhD, Assistant Professor of Oncology and Director of the Tumor Immunology and Immunotherapy Laboratory in Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland. *Cancer Biology & Therapy*, March/April 2003, 2 (2): 161-163.

LANGUAGES: English, Spanish, French